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Purpose of review
Tuberculosis (TB) remains a global emergency and continues to kill 1.7 million people
globally each year. Drug-resistant TB is now well established throughout the world
and most TB patients are not being screened for drug resistance due to lack of
laboratory resources and rapid accurate point-of-care tests. Accurate and rapid
diagnosis of TB and drug-resistant TB is of paramount importance in establishing
appropriate clinical management and infection control measures. During the past
decade, there have been significant advances in diagnostic technologies for TB and
drug-resistant TB. The purpose of this article is to review the current data,
recommendations and evidence base for these tests.
Recent findings
Second-line drug susceptibility testing (DST) is complex and expensive. Automated
liquid culture systems and molecular line probe assays are recommended by the WHO
as the current ‘gold standard’ for first-line DST. Liquid culture DST for aminoglycosides,
polypeptides and fluoroquinolones has been shown to have relatively good reliability
and reproducibility for diagnosis of extensively drug-resistant TB; however, DST for
other second-line drugs (ethionamide, prothionamide, cycloserine, terizidone, para-
aminosalicylic acid, clofazimine, amoxicillin-clavulanate, clarithromycin, linezolid) is not
recommended. Automated liquid culture systems are currently recommended by the
WHO as the ‘gold standard’ for second-line DST.
Summary
In this review, we describe the phenotypic and genotypic methods currently available for
the diagnosis of TB and drug-resistant forms of Mycobacterium tuberculosis and
discuss future prospects for TB diagnostics. Current technologies for the detection of
drug resistant M. tuberculosis vary greatly in terms of turnaround time, cost and
complexity. Ultimately, the ‘holy grail’ diagnostic for TB must fulfil all technical
specifications for a good point-of-care test, screen for drug resistance concurrently and
be adaptable to the various health system levels and to countries with diverse economic
status and TB burden.
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1070-5287Introduction
Tuberculosis (TB) remains a global emergency and con-
tinues to kill 1.7 million people globally, each year.
During the past decade, there have been significant
advances in diagnostic technologies for TB. Increase in
both public and private investment and the joint efforts
of the World Health Organisation (WHO) and the
Foundation for Innovative New Diagnostics (FIND)
have facilitated this process [1]. FIND are co-develop-
ing new diagnostics technologies that are targeted for useopyright © Lippincott Williams & Wilkins. Unautho
1070-5287  2011 Wolters Kluwer Health | Lippincott Williams & Wilkinsat three health system levels: reference laboratory, micro-
scopy centre/peripheral laboratories and primary health-
care level/health post. Such new and improved diagnos-
tics technologies are urgently required for the global fight
against the TB epidemic. Liquid media for culture and
drug susceptibility testing (DST), molecular line probe
assays for screening people at risk of multiple drug-
resistant TB (MDR-TB), LED microscopy and noncom-
mercial culture and DST have all been endorsed by the
WHO since 2007 (Fig. 1). Endorsement of technology by
theWHO combined with FIND’s negotiations on pricingrized reproduction of this article is prohibited.
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Key points
 New and improved methods for the detection of
drug-resistant tuberculosis (TB) are described in
this review.
 Phenotypic M. tuberculosis drug susceptibility test-
ing (DST) methods are inexpensive and accurate
but time consuming.
 Genotypic M. tuberculosis DST methods are rapid
and accurate but expensive.
 Second-line DST is complex and expensive.
 The variousM. tuberculosisDSTmethods described
are all currently required to suit the diverse
economic status and TB burden of countries world-
wide and to suit the different health system levels.with industry has made new and improved diagnostics
more affordable and feasible, for the first time, for devel-
oping countries [1].
Widespread incorrect use of isoniazid and rifampicin over
the past decades has resulted in emergence and spread of
MDR-TB and extensively drug-resistant TB (XDR-TB)
globally. These difficult to treat, drug-resistant forms of
TB are increasingly seen in Asia, eastern Europe, South
America and sub-Saharan Africa, disrupting TB and HIV
control programmes [3,4,5,6,7,8] (Fig. 2). Each year,
an estimated half a million MDR-TB cases develop, of
which only around 7% are diagnosed. In the 27 high-
burden MDR-TB countries, only 1% of new TB patients
had DST performed in 2008 because of a lack of labora-
tory capacity [8,9]. As a result, patients with drug-
resistant TB may be inappropriately treated, drug-resist-
ant Mycobacterium tuberculosis strains may spread in the
community and amplification of resistance may occur
[10]. Accurate and rapid diagnosis of drug-resistant
TB is of paramount importance in establishing appro-
priate clinical management and infection control
measures [1,7].
The ‘gold standard’ method forM. tuberculosisDST is the
indirect 1% proportion method. This method was devel-
oped in the 1960s and is still used in many laboratories,
especially in developing countries, because it is inexpen-
sive and easily accessible [11]. Because of the long turn-
around time (weeks to months) associated with such
conventional DST methods, several new approaches
have been developed for faster detection of drug-resist-opyright © Lippincott Williams & Wilkins. Unauth
Figure 1 The Stop-TB Partnership’s new diagnostics working grou
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CRI, colorimetric redox indicator assay; DST, drug susceptibility test; LED
infection; MODS, microscopic observation drug susceptibility; NAAT, nucleic
Manual NAAT: technology for MTB drug susceptibility testing.

Manual NA
NAAT: technology for MTB detection at the community healthcare level. Techant TB. These methods can be divided into two
categories: culture-based or phenotypic methods and
nucleic acid-based or genotypic methods.
DST for first-line anti-TB drugs is most accurate for
rifampicin (RIF) and isoniazid (INH) and less reliable
and reproducible for streptomycin, ethambutol (EMB)
and pyrazinamide (PZA). RIF resistance is a valid and
reliable indicator of MDR-TB [12]. Automated liquid
culture systems andmolecular line probe assays are recom-
mended by the WHO as the current ‘gold standard’ for
first-line DST. Second-line DST is complex and expens-
ive. Liquid culture DST for aminoglycosides, poly-
peptides and fluoroquinolones has been shown to have
relatively good reliability and reproducibility for diagnosis
of XDR-TB; however, DST for other second-line drugsorized reproduction of this article is prohibited.
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Figure 2 Estimated percentage of multiple drug resistant tuberculosis among new tuberculosis cases, 2008a
, 0 to <3; , 3 to <6; , 6 to <12; , 12 to <18; , 18;‘, no data available; , subnational data only. Reproduced with
permission from [2].(ethionamide, prothionamide, cycloserine, terizidone,
para-aminosalicylic acid, clofazimine, amoxicillin-clavula-
nate, clarithromycin, linezolid) is not recommended [12].
Automated liquid culture systems are currently recom-
mendedby theWHOas the ‘gold standard’ for second-line
DST [12,13,14]. In this review, we describe the pheno-
typic and genotypic methods currently available for the
diagnosis of drug-resistant forms of M. tuberculosis and
discuss future prospects for TB diagnostics.Definitions of drug-resistant tuberculosis
MDR-TB is defined as resistance to the two key first-line
anti-TB drugs, INH and RIF. XDR-TB is defined as TB
caused by strains of M. tuberculosis resistant to at least
INH and RIF (i.e. MDR-TB), plus any fluoroquinolone
and at least one of three injectable drugs used in anti-TB
treatment, capreomycin, kanamycin or amikacin [7,8].Phenotypic drug susceptibility testing
Culture-based or phenotypic DST methods are accurate
and inexpensive but are disadvantaged by relying on the
growth onM. tuberculosis, rendering them time consuming
[15]. Phenotypic DSTmethods are performed on solid or
liquid media as direct or indirect tests. Direct methodsopyright © Lippincott Williams & Wilkins. Unauthoare those used directly on patient samples where a set
of drug-containing and drug-free media is inoculated
directly with a patient specimen. Indirect DST involves
inoculation of drug-containing media with a pure culture
grown from the original patient specimen [12]. Commer-
cial automated liquid culture DST methods have a
relatively short turnaround time (because of sensitive
automation and M. tuberculosis’s relatively faster growth
in liquid compared with solid media) and are highly
accurate but are expensive and require specialist equip-
ment [16]. The WHO considered evidence for the
accuracy and role of a number of noncommercial cul-
ture-based methods that utilize widely available and
inexpensive laboratory equipment and supplies and
recommended selected methods as interim measures
while capacity for automated culture DST and/or geno-
typic DST are being developed [1,17,18]. Microscopic
observation drug susceptibility (MODS) [17,19–21] and
colorimetric redox indicator (CRI) [22,23]methods and the
nitrate reductase assay (NRA) [15,24,25] receivedWHO
approval [17]. Such methods have similar accuracy to
commercial liquid culture systems and could be imple-
mented in high-burden, low-income settings with mini-
mum cost; however, these tests require extensive operator
training, standardization and quality assurance before
implementation [1].rized reproduction of this article is prohibited.
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testing
The most commonly used commercially available auto-
mated liquid culture DST system is the BACTEC
MGIT 960 system with the BACTEC MGIT 960 SIRE
kit (Becton Dickinson, Franklin Lakes, New Jersey,
USA). This is an indirect qualitative method for the
detection of first-line drug resistance to streptomycin,
INH, RIF and EMB [16]. The test, which is performed
on M. tuberculosis complex (MTBC) positive culture,
takes approximately 4–13 days to obtain a result. The
test was developed with critical concentrations for
streptomycin (1mg/ml), INH (0.1mg/ml), RIF (1mg/
ml) and EMB (5mg/ml) that are slightly lower than
the critical concentrations used in the proportion
method test, in order to avoid false susceptibility
results. A PZA DST kit is also available for the MGIT
system. The test is based on growth of the MTBC
isolate in a drug-containing tube compared with a
drug-free tube (growth control). Continuous analysis
of fluorescence by the BACTEC MGIT 960 instrument
in the drug-containing tube compared with the fluor-
escence of the growth control tube is used to determine
susceptibility results. The instrument automatically
interprets these results and reports a susceptible or
resistant result [16,26]. This method has been demon-
strated to be equivalent to the proportion method
standard and has been endorsed by the WHO
[27,28,29]. Other nonradiometric automated liquid cul-
ture systems capable of M. tuberculosis DST include the
BacT/ALERT MB (bioMerieux Inc., Durham, North
Carolina, USA) system and the VersaTREK system
(Trek Diagnostic Systems, West Lake, Ohio, USA)
[28,30].Microscopic observation drug susceptibility
MODS is a liquid culture-based test that can detect
members of the MTBC in sputum and can assess INH
and RIF susceptibility either directly on sputum samples
or indirectly on M. tuberculosis isolates. This method
utilizes the markedly faster growth of M. tuberculosis in
liquid media than on solid media and the characteristic
microscopic cording appearance ofM. tuberculosis in liquid
media. Cultures containing supplemented Middlebrook
7H9 medium are microscopically examined for micro-
colonies which can be detected in a median of 7 days.
INH and RIF can be incorporated in the testing process
to enable MDR-TB detection [21]. Drug-free and drug-
containing media are inoculated with specimens from
patients orM. tuberculosis isolates, and cultures are micro-
scopically examined. Growth of M. tuberculosis in drug-
free media indicates a positive culture, whereas growth of
M. tuberculosis in both drug-free and drug-containing
media indicates resistance [17,19,21].opyright © Lippincott Williams & Wilkins. UnauthMeta-analysis of direct and combined (direct and indir-
ect) testing of MODS performed by the WHO indicates
that the method is 98% sensitive and 99% specific for
the detection of RIF resistance and 91% sensitive for
INH resistance [18]. High sensitivity and specificity are
retained in direct MODS testing. The capability to per-
form MODS DST directly on sputum samples in a short
timescale and the low cost of reagents are advantages of
this technique [21], but the WHO only endorses its
implementation at reference laboratory level [18].Colorimetric redox indicator methods
The principal of CRI methods is the reduction of a
coloured indicator which is added to the culture medium
after cultured M. tuberculosis have been exposed to the
test antibiotic [30]. Drug resistance is detected by a
change in colour of the indicator, which is directly pro-
portional to the number of viable mycobacteria remaining
in the medium after exposure to the antibiotic. Different
indicators have been evaluated giving comparable results
in agreement with the proportion method reference
standard. Among the different growth indicators used
are the tetrazolium salts XTT and MTT and the redox
indicators Alamar blue and resazurin [31].
Data analysis performed by the WHO showed that CRI
methods are highly sensitive and specific for the detec-
tion of RIF and INH resistance (98 and 97% sensitive
respectively; 99 and 98% specific, respectively) and these
methods were endorsed by the WHO in 2010 [18]. CRI
methods are indirect tests performed on M. tuberculosis
isolates, therefore turnaround time to results is not faster
than conventional phenotypic DST [18,31].Nitrate reductase assay
The NRA, also known as the Griess method, is a simple
technique based on the capacity of M. tuberculosis to
reduce nitrate to nitrite. By incorporating 1mg/ml
potassium nitrate (KNO3) in Lowenstein–Jensen med-
ium, the reduction of nitrate can be detected using the
Griess reagent, which produces a coloured reaction [11]. In
the presence of antibiotic at the critical concentration,
development of a red–pink colour in the medium
represents resistance. Susceptible strains lose the capacity
to reduce nitrate in the presence of the antibiotic, thus
produce no colour. The use of nitrate reduction as an
indicator of growth, before colonies can be seen macro-
scopically, reduces the turnaround time to results
compared with conventional methods [11]. The WHO
recommends [18] that the NRA be used as a direct test
on smear-positive sputum specimens or as an indirect test
on M. tuberculosis isolates grown from conventional solid
culture. Data on combined (direct and indirect) use
showed that the NRA is 97% sensitive and 100% specificorized reproduction of this article is prohibited.
C138 Infectious diseasesfor the detection of RIF resistance and 97% sensitive and
99% specific for detection of INH resistance [18]. Diag-
nostic accuracy data for direct testing alone does not differ
significantly. Reagents for NRA are nonproprietary and
relatively inexpensive, but indirect testing using NRA is
not faster than conventional phenotypic DST using solid
media [11,18].
Other new and existing phenotypic DSTmethods, which
have not been endorsed by the WHO, are reviewed
elsewhere [30] and include the slide-culture technique,
mycobacteriophage-based methods including the Fas-
tPlaque assay and luciferase reporter phages, the E-test,
the thin-layer agar method and the TK medium.Genotypic drug susceptibility testing
Several molecular diagnostics assays are commercially
available for the detection of the MTBC, including the
COBAS TaqMan MTB PCR test (Roche Diagnostics,
Basel, Switzerland) [32], artus M. tuberculosis PCR kits
(Qiagen, Hamburg, Germany) [33] and the Amplified
Mycobacterium Tuberculosis Direct (AMTD) test
(Gen-Probe Inc., San Diego, California, USA) [34].
Recently, commercial and ‘in-house’ molecular diagnos-
tics assays for the detection of the MTBC and the simul-
taneous detection of drug resistance have been described
[35–40]. These methods are generally nucleic acid ampli-
fication tests (NAATs) and include hybridization assays
(e.g. line probe assays), real-time PCR assays (often using
molecular beacon probes) and sequencing assays. The
most common mutations associated with drug resistance
havebeendescribed andare publically available on theTB
drug resistance mutation database [41]. Genotypic DST
methods target these well characterized resistance associ-
ated mutations to identify drug resistant M. tuberculosis.
One of themost important drugs in the treatment of TB is
RIF and RIF resistance is particularly suitable for geno-
typic DST because 95% of RIF resistance associated
mutations are present in an 81bp region of the rpoB gene
known as the rifampicin resistance determining region
(RRDR) [36]. Molecular detection of resistance to other
anti-TBdrugs, such as INHand some second-line drugs, is
more complex and requires detection of mutations in
multiple genes for good correlation with phenotypic
results. Accurate genotypic DST for first-line and sec-
ond-line anti-TB drugs is, therefore, technically challen-
ging. Improved multiplex-PCR technology and improved
multianalyte detection technology will make genotypic
DST a more powerful technique in future.Line probe assays
Line probe assays were endorsed by theWHO in 2008 for
molecular detection of drug resistance from smear-
positive patients at risk of MDR-TB [42]. Two commer-opyright © Lippincott Williams & Wilkins. Unauthocial LPAs are currently available: the INNO-LiPA
Rif.TB test (Innogenetics NV, Gent, Belgium) and the
GenoType MTBDRplus test (Hain Lifescience GmbH,
Nehren, Germany) [29]. LPAs use a PCR/hybridization
technique to identify members of the MTBC while
simultaneously identifying drug-resistant strains by
detecting the most common single nucleotide polymor-
phorisms (SNPs) associated with resistance. Meta-
analyses have shown that LPAs are highly accurate for
the detection of first-line drug resistance, especially in
smear-positive sputum specimens [29,39,43]. WHO
analysis of systematic reviews and meta-analyses showed
that LPAs are highly sensitive (97%) and specific
(99%) for the detection of RIF resistance, alone or in
combination with INH (sensitivity 90%; specificity
99%), on isolates of M. tuberculosis and on smear-
positive sputum specimens. Accuracy for detection of
MDR-TB was 99%, which remained unchanged when
RIF resistance alone was used as a proxy marker for
MDR-TB [42]. Hain Lifesciences released the Geno-
Type MTBDRsl test in 2009, designed to test for resist-
ance to second-line anti-TB drugs (fluoroquinolones,
ethambutol, aminoglycosides and cyclic peptides), and
which can be used in combination with the MTBDRplus
test to identify XDR-TB [44–46]. The major advantage
of LPAs is that they can be performed directly on smear-
positive sputum samples, giving rapid (approximately
5 h) drug susceptibility results without the need for
culture. Many laboratories now use LPAs as the primary
method for DST on cultured isolates of M. tuberculosis,
replacing phenotypic DST [29]. The disadvantages of
LPAs are that they are labour intensive and require
highly trained personnel and dedicated laboratory space
and equipment [47].Xpert Mycobacterium tuberculosis/rifampicin
assay
One of the most promising new point-of-care (POC)
diagnostics technologies to be developed in recent years
is the GeneXpert (Cepheid, Sunnyvale, California, USA).
The GeneXpert machine is a fully automated closed
system that performs both sample preparation and real-
time PCR, producing results in less than 2 h (Fig. 3). The
Xpert MTB/RIF test, designed for the GeneXpert sys-
tem, is capable of detecting the MTBC while simul-
taneously detecting RIF resistance (targeting the RRDR
of the rpoB gene). Analytical sensitivity and specificity is
100% according to a recent study using RIF resistant and
sensitive M. tuberculosis isolates and nontuberculosis
bacteria, fungi and viruses [36]. A clinical validation
study of the method was performed using 107 clinical
sputum samples from suspected TB cases in Vietnam.
The Xpert MTB/RIF test detected 29/29 (100% sensi-
tivity) smear-positive culture-positive cases and 33/39
(84.6% sensitivity) smear-negative culture-positive cases,rized reproduction of this article is prohibited.
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Figure 3 Cepheid GeneXpert IV and Xpert MTB/RIF test car-
tridge
From Cepheid, reproduced with permission.and M. tuberculosis was not detected in 25/25 (100%
specificity) of the culture-negative samples. In the same
study, 64 smear-positive culture-positive sputa from
patients previously treated for TB in Uganda were tested
and the Xpert MTB/RIF test detected 63/64 (98.4%
sensitivity) culture-positive cases and nine of nine
(100% sensitivity) cases of RIF resistance. RIF resistance
was excluded in 55/55 susceptible cases – 100% speci-
ficity [48]. In a recent multicentre (Peru, Azerbaijan,
South Africa and India) evaluation study of 1730 patients
with suspected drug-sensitive or multidrug-resistant pul-
monary TB published in the New England Journal of
Medicine, a single Xpert MTB/RIF test was 98.2 and
72.5% sensitive on smear-positive (n¼ 561) and smear-
negative (n¼ 171) TB patients, respectively, and the test
was 99.2% specific [49]. Compared to phenotypic DST,
theMTB/RIF test correctly identified 200 of 205 patients
(97.6% sensitive) with RIF-resistant bacteria and 504 of
514 (98.1% specific) with RIF-sensitive bacteria [49].
The assay is designed for direct genotypic DST from
unprocessed sputum or sediment from a concentrated
specimen. Sample reagent is poured into the sample
tube, incubated for 15min, pippetted into the Xpert
cartridge and inserted into the GeneXpert machine for
processing. Highly trained staff are not required to run
the machine or interpret the results [10]. The Xpert
MTB/RIF test has the potential to be used in moderately
equipped laboratories; however, it is unlikely to be used
as a POC diagnostic test in the most peripheral settings,opyright © Lippincott Williams & Wilkins. Unauthlike rural health centres, due to poor infrastructure and
limited resources [50]. The FIND-negotiated price for a
four testing module GeneXpert machine is approxi-
mately US$ 17 000 and the Xpert MTB/RIF tests cost
approximately US$ 17 per cartridge, but the price is likely
to decrease as a result of increased sales related to
endorsement of the technology by the WHO in Decem-
ber 2010 [10,50].
There is an urgent need for research on the implementa-
tion of the Xpert MTB/RIF test to determine its per-
formance characteristics and the impact it has on patient
outcomes when used in a variety of primary healthcare
settings covering the wide range of available infrastruc-
ture. Other variables that may affect the tests overall
performance are HIV prevalence, strain diversity, preva-
lence of specific drug resistance-conferring mutations,
patient-related diagnostic delays and default rates [10].
Future prospects
The ideal TB diagnostic would be a simple, low-tech-
nology, rapid, POC test with accurate results that could
simultaneously identify drug resistance. In 2009, an
expert group led byMedecins Sans Frontieres developed
a set of minimum technical specifications for new POC
TB tests [51]. No existing test meets all of these speci-
fications, although the Xpert MTB/RIF test meets the
majority. Increased availability of funding and growing
interest in new TB diagnostics and biomarkers have
encouraged the development of several new POC tests
for TB including improved serologic assays, hand-held
molecular devices, breath-based assays for the detection
of volatile organic compounds, microchip technologies
and proteomics-based and metabolomics-based tests
[29]. As POC test technology advances, new POC TB
and drug-resistant TB tests reach the market and com-
petition increases, prices for such tests should reduce
significantly [10,50,52].
Conclusion
Current technologies for the detection of drug-resistant
M. tuberculosis vary greatly in terms of turnaround time,
cost and complexity. Ultimately, the ‘holy grail’ TB
diagnostic test that fulfils all technical specifications for
a good POC test may be developed. Until then, different
DST methods are required, suitable for countries with
diverse economic status and TB burden and for the
various health system levels.
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